Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 5 of 5 publications.
Skip to main content
Ahn JH, da Silva Pedrosa M, Lopez LR, Tibbs TN, Jeyachandran JN, Vignieri EE, Rothemich A, Cumming I, Irmscher AD, Haswell CJ, Zamboni WC, Yu YA, Ellermann M, Denson LA, Arthur JC. Intestinal E. coli-produced yersiniabactin promotes profibrotic macrophages in Crohn's disease. Cell Host Microbe. 2025 Jan 8;33(1):71-88.e9. doi: 10.1016/j.chom.2024.11.012
Loftus EV, Davis KL, Wang CC, Dastani H, Luo A. Treatment patterns, complications, and disease relapse in a real-world population of patients with moderate-to-severe ulcerative colitis initiating immunomodulator therapy. Inflamm Bowel Dis. 2014 Aug;20(8):1361-7. doi: 10.1097/MIB.0000000000000089
Long MD, Hutfless S, Kappelman MD, Khalili H, Kaplan GG, Bernstein CN, Colombel JF, Gower-Rousseau C, Herrinton L, Velayos F, Loftus EVJr, Ananthakrishnan AN, Nguyen GC, Sonnenberg A, Chan A, Sandler RS, Atreja A, Shah SA, Rothman KJ, Leleiko NS, Bright R, Boffetta P, Myers KD, Sands BE. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2014 Feb;20(2):398-415. doi: 10.1097/01.MIB.0000435441.30107.8b
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
Debanjali M, Hodgkins P, Yen L, Solomon D, Davis KL, Cohen R. Adherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis: impact on all-cause healthcare costs. Inflamm Bowel Dis. 2009 Dec 1;15(12):S32.